Hepatitis B Booster Dose Recommendations

Standard Booster Dosing

The Centers for Disease Control and Prevention recommends administering a single standard adult dose of hepatitis B vaccine (10 μg Recombivax HB or 20 μg Engerix-B) as the booster dose for previously vaccinated individuals at ongoing risk of hepatitis B exposure 1
The standard booster dose should match standard adult formulations: Recombivax HB (10 μg, 1.0 mL) intramuscularly, Engerix-B (20 μg, 1.0 mL) intramuscularly, and Heplisav-B (20 μg, 0.5 mL) intramuscularly 2
For Twinrix (combination HepA-HepB), the booster dose is 20 μg HBsAg component (1.0 mL) intramuscularly 3

For completely vaccinated healthcare personnel with anti-HBs <10 mIU/mL, the Centers for Disease Control and Prevention recommends giving one additional standard dose of HepB vaccine, followed by anti-HBs testing 1-2 months later 1
Hemodialysis patients require higher booster doses: 40 μg (either two 20 μg doses of Engerix-B or two 10 μg doses of Recombivax HB given at different sites), with annual anti-HBs testing and booster administration when levels decline to <10 mIU/mL 1, 2
For HIV-infected persons, hematopoietic stem-cell transplant recipients, and persons receiving chemotherapy, consider high-dose boosters (40 μg/dose for adults) with annual anti-HBs testing and booster doses for those with ongoing risk for exposure 1, 3

Test anti-HBs 1-2 months after booster administration for healthcare personnel, immunocompromised persons, and sex partners of HBsAg-positive individuals, using assays that detect protective concentrations ≥10 mIU/mL (e.g., ELISA) 1, 4
Do not test after boosters in hemodialysis patients 1

If a person fails to achieve anti-HBs ≥10 mIU/mL after a single booster dose, they should receive a complete second 3-dose series, with retesting of anti-HBs 1-2 months later 1, 4
Persons who remain non-responsive after 6 total doses should be tested for HBsAg to rule out chronic infection 4

Most patients develop protective hepatitis B immunity within 2-4 weeks after receiving a booster dose, with detectable protective titers (≥10 mIU/mL) appearing at approximately 4 weeks post-booster in the majority of responders 5

Anti-HBs ≥10 mIU/mL indicates adequate immunity in immunocompetent individuals who previously completed a primary vaccination series 6
Among persons initially vaccinated and later found to have anti-HBs <10 mIU/mL, a single challenge/booster dose results in anti-HBs levels ≥10 mIU/mL in 60-97% of those tested 5
Immunocompetent persons with a response ≥10 mIU/mL following a challenge dose are considered protected, regardless of subsequent declines in anti-HBs 5

Most persons (88%) who receive a challenge dose 30 years after primary HepB vaccination develop an antibody response ≥10 mIU/mL, indicating persistent immunity 6